HAMBURG, Germany, Oct. 5, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd. (Tokyo and Osaka Stock Exchanges:4507), to identify small molecule modulators of various protein-protein interaction targets. Evotec will apply its proprietary and integrated fragment-based drug discovery platform, EVOlution™ to the programme. The key benefit of this platform for the selection of target-specific strategies is its versatility, combining biochemical and biophysical techniques including nuclear magnetic resonance (NMR), surface plasmon resonance (SPR) and X-ray crystallography. Within this collaboration, EVOlution™ will be used to investigate protein-protein interactions on targets selected by Shionogi. Dr Mario Polywka, COO of Evotec stated: "We are extremely pleased that Shionogi has decided to undertake these projects with Evotec. Our proprietary fragment-based drug discovery platform has shown that it adds significant value to our partner's programmes and we look forward to supporting Shionogi in finding novel treatments for inflammation and infectious diseases." No financial details are disclosed. About EVOlution TM EVOlution TM is Evotec's fragment-based drug discovery platform which combines biochemical and biophysical techniques including nuclear magnetic resonance (NMR), surface plasmon resonance (SPR) and X-ray crystallography for the screening of low molecular weight compounds and fragments. By the combination of the orthogonal screening technologies, Evotec's fragment screening platform is capable of screening a more diverse set of biological targets than other fragment screening approaches, as well as being able to screen the fragments in a high-throughput mode. The benefit of this is the ability to identify active fragments for numerous classes of biological targets in a short space of time. For further information, please see: www.evotec.com/ fragment-based drug discovery About Fragment-based Drug Discovery Fragment-based drug discovery (FBDD) is a drug discovery strategy that utilises very small molecules - fragments of more complex molecules – to generate efficient starting points for drug discovery. This approach thus provides the opportunity to effectively manage the molecular weight and overall complexity of drug candidates, a recognised success factor in drug development.